Adicet Bio Inc

NASDAQ ACET

Data sourced from

and

Download Data

Adicet Bio Inc Cash Flow Coverage Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: -743.31%

Adicet Bio Inc Cash Flow Coverage Ratio 1 year YoY Change (%) is -743.31% for the quarter ending March 31, 2024, a 58.07% change year over year. The cash flow coverage ratio evaluates a company's ability to cover its interest expense with its operating cash flow after deducting capital expenditures. It is calculated by dividing the difference between operating cash flow and capital expenditures by interest expense. This ratio indicates the company's ability to generate enough cash flow to service its interest payments. A higher ratio signifies better coverage and financial stability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Adicet Bio Inc Cash Flow Coverage Ratio for the quarter ending March 31, 2023 was -1,368.89, a -1,772.78% change year over year.
Adicet Bio Inc Cash Flow Coverage Ratio for the quarter ending March 31, 2022 was 81.83, a 125.89% change year over year.
Adicet Bio Inc Cash Flow Coverage Ratio for the quarter ending March 31, 2021 was -316.08, a -1,077.03% change year over year.
Adicet Bio Inc Cash Flow Coverage Ratio for the quarter ending March 31, 2020 was -26.85.

NASDAQ: ACET

Adicet Bio Inc

CEO	Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
IPO Date	Jan. 26, 2018
Location	United States
Headquarters	200 Clarendon Street, Boston, MA, United States, 02116
Employees	143
Sector	Healthcare
Industry	Biotechnology

Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Key trends